# Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

> **NCT05610956** · EARLY_PHASE1 · RECRUITING · sponsor: **Tanta University** · enrollment: 60 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** conventional treatment

## Key facts

- **NCT ID:** NCT05610956
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610956, "Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05610956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*